Patents by Inventor Marshall Porter
Marshall Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250034637Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: ApplicationFiled: August 8, 2024Publication date: January 30, 2025Applicant: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Patent number: 12091714Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: GrantFiled: February 21, 2023Date of Patent: September 17, 2024Assignee: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Publication number: 20230332222Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: ApplicationFiled: February 21, 2023Publication date: October 19, 2023Applicant: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Patent number: 11613778Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: GrantFiled: January 25, 2021Date of Patent: March 28, 2023Assignee: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Patent number: 11150233Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.Type: GrantFiled: September 28, 2018Date of Patent: October 19, 2021Assignee: Roche Sequencing Solutions, Inc.Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
-
Publication number: 20210230683Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: ApplicationFiled: January 25, 2021Publication date: July 29, 2021Applicant: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Patent number: 10934582Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: GrantFiled: July 23, 2019Date of Patent: March 2, 2021Assignee: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Publication number: 20200216887Abstract: A method is provided for preparing nanopore sequencing complexes in membranes for sequencing of polymers, e.g., polynucleotides and polypeptides. The nanopore sequencing complex is formed by the sequential linking of an enzyme to a nanopore that is inserted in a membrane, and of a polymer to the enzyme. Alternatively, the nanopore sequencing complex is formed by linking a preformed enzyme-polymer complex to a nanopore that is inserted in a membrane. The enzyme polymer complex is interchangeable.Type: ApplicationFiled: January 20, 2017Publication date: July 9, 2020Applicant: Genia Technologies, Inc.Inventors: Timothy Kellogg Craig, Christos Tzitzilonis, Alexander H. Yang, Liv E. Jensen, Marshall Porter, Charlotte Yang, Corissa Harris, Matt Dipetro
-
Publication number: 20190376134Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The a-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: ApplicationFiled: July 23, 2019Publication date: December 12, 2019Applicant: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DePietro, Corissa Harris, Marshall Porter
-
Publication number: 20190079067Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.Type: ApplicationFiled: September 28, 2018Publication date: March 14, 2019Applicant: GENIA TECHNOLOGIES, INC.Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
-
Publication number: 20180002750Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: ApplicationFiled: June 29, 2017Publication date: January 4, 2018Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Publication number: 20060051569Abstract: A vehicle bumper (20) integrates rigid and flexible components into a single co-injection molded structure. In a preferred embodiment, a flexible fascia (58) is provided with integrated rigid fastener brackets (62, 66, 70, 71), energy absorption structure and head lamp brackets and housings (62). A method for manufacturing such a bumper provides for the injection of two different plastic materials during the same molding process. The flexible plastic material first injected into the mold. Then, the rigid plastic material is injected at gates located where the rigid material is desired. In one embodiment, the rigid material is completely contained within the flexible material. The rigid material may be either a higher stiffness plastic or a fiber reinforced plastic.Type: ApplicationFiled: October 31, 2005Publication date: March 9, 2006Inventors: Marshall Porter, Norman Guschewski, Michael Smith, Keith Korte, Todd Parker, Russell York